135 related articles for article (PubMed ID: 7480927)
21. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
Segura I; García-Bolao I
Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
[TBL] [Abstract][Full Text] [Related]
22. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
[TBL] [Abstract][Full Text] [Related]
23. Intralesional glucantime in Leishmania braziliensis braziliensis infections.
Barrios LA; Costa JM; Netto EM; Vexenat CO; Cuba CC; Marsden PD
Trans R Soc Trop Med Hyg; 1986; 80(1):173-4. PubMed ID: 3726989
[No Abstract] [Full Text] [Related]
24. First report on ototoxicity of meglumine antimoniate.
Valete-Rosalino CM; Araujo-Melo MH; Bezerra DC; Barcelos RO; Melo-Ferreira Vd; Torraca TS; Martins AC; Moreira JS; Vargas MC; Braga FP; Salgueiro Mde M; Saheki MN; Schubach AO
Rev Inst Med Trop Sao Paulo; 2014; 56(5):439-42. PubMed ID: 25229226
[TBL] [Abstract][Full Text] [Related]
25. Retention of antimony in hair during leishmaniasis treatment.
Dorea JG; Merchan-Hamann E; Ryan DE; Holzbecher J
Clin Chim Acta; 1989 Feb; 179(3):341-5. PubMed ID: 2714007
[No Abstract] [Full Text] [Related]
26. [A case of mucocutaneous leishmaniasis treated with success with a low dose of pentavalent antimonial].
Amato VS; de Oliveira LS; Silva AC; Machado FR; Amato JG; Nicodemo AC; Amato Neto V
Rev Soc Bras Med Trop; 1998; 31(2):221-4. PubMed ID: 9608241
[TBL] [Abstract][Full Text] [Related]
27. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of three chemotherapeutic schemes with meglumine antimoniate in the treatment of visceral leishmaniasis in the State of Pará, Brazil.
Marsden PD
Rev Inst Med Trop Sao Paulo; 1993; 35(6):589. PubMed ID: 7997767
[No Abstract] [Full Text] [Related]
29. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis.
Rodrigues ML; Costa RS; Souza CS; Foss NT; Roselino AM
Rev Inst Med Trop Sao Paulo; 1999; 41(1):33-7. PubMed ID: 10436668
[TBL] [Abstract][Full Text] [Related]
30. Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy.
Hantson P; Luyasu S; Haufroid V; Lambert M
Pharmacotherapy; 2000 Sep; 20(9):1141-3. PubMed ID: 10999510
[TBL] [Abstract][Full Text] [Related]
31. Meglumine antimoniate-induced pancreatitis.
Torrús D; Massa B; Boix V; Portilla J; Pérez-Mateo M
Am J Gastroenterol; 1996 Apr; 91(4):820-1. PubMed ID: 8677970
[No Abstract] [Full Text] [Related]
32. Combined antimonial allopurinol therapy in mucosal leishmaniasis.
Sampaio RN; Marchán EM; Vexenat A; Tristão RJ; Marsden PD
Mem Inst Oswaldo Cruz; 1990; 85(3):373-4. PubMed ID: 2134714
[No Abstract] [Full Text] [Related]
33. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
Soto J; Hernandez N; Mejia H; Grogl M; Berman J
Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
[TBL] [Abstract][Full Text] [Related]
34. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol.
Antezana G; Zeballos R; Mendoza C; Lyevre P; Valda L; Cardenas F; Noriega I; Ugarte H; Dedet JP
Trans R Soc Trop Med Hyg; 1992; 86(1):31-3. PubMed ID: 1566297
[TBL] [Abstract][Full Text] [Related]
35. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
Trinchieri V; Ferone U; Monacelli M; Isceri L; Proietti F; Sorice F
Riv Eur Sci Med Farmacol; 1996; 18(2):49-51. PubMed ID: 9213843
[TBL] [Abstract][Full Text] [Related]
36. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
37. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
[TBL] [Abstract][Full Text] [Related]
38. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.
Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN
Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762
[TBL] [Abstract][Full Text] [Related]
39. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F
Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
